Business Trends
Supernus–Indivior Merger Signals CNS Expansion as Strategic Deal Overshadows Earnings Miss
Supernus Pharmaceuticals (SUPN) rose after announcing a merger with Indivior and raising its 2026 outlook. Investors looked beyond a non-cash impairment and earnings miss, focusing on stronger revenue growth, higher guidance, and the strategic expansion of its CNS business.